Daniel D. Shoemaker
2015
In 2015, Daniel D. Shoemaker earned a total compensation of $956.8K as Chief Scientific Officer at Fate Therapeutics, a 26% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $50,563 |
|---|---|
| Option Awards | $238,714 |
| Salary | $317,555 |
| Stock Awards | $349,965 |
| Total | $956,797 |
Shoemaker received $350K in stock awards, accounting for 37% of the total pay in 2015.
Shoemaker also received $50.6K in non-equity incentive plan, $238.7K in option awards and $317.6K in salary.
Rankings
In 2015, Daniel D. Shoemaker's compensation ranked 8,180th out of 13,638 executives tracked by ExecPay. In other words, Shoemaker earned more than 40.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,180 out of 13,638 | 40th |
Division Manufacturing | 3,121 out of 5,187 | 40th |
Major group Chemicals And Allied Products | 1,137 out of 1,857 | 39th |
Industry group Drugs | 916 out of 1,531 | 40th |
Industry Biological Products, Except Diagnostic Substances | 160 out of 260 | 39th |
Source: SEC filing on March 22, 2017.
Shoemaker's colleagues
We found three more compensation records of executives who worked with Daniel D. Shoemaker at Fate Therapeutics in 2015.